Now Available
ZELNORMTM (tegaserod) is a serotonin-4 (5-HT4) receptor agonist indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Thank you for your request.

A ZELNORM representative will contact you shortly.

There was an error sending you an email.

We're looking into this issue.

Request a visit from your
ZELNORM representative

A representative is available to provide more information on ZELNORM, including mechanism of action, clinical trials, efficacy, safety, and more. Simply fill out the form below to request a visit.

First Name Please fill in a correct name (Letters only)
Last Name Please fill in a correct name (Letters only)
Email Incorrect Email (email@domain.com)
Phone Number Please enter a 10-digit phone number
(123-456-7890)
ZIP Code Please enter a 5-digit
ZIP Code (12345)

Select the topics that most interest you (OPTIONAL)

See More

Indication and Important
Safety Information

Indication

ZELNORMTM (tegaserod) is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Important Safety Information

Contraindications

ZELNORM is contraindicated in patients with:

  • History of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina
  • History of ischemic colitis or other forms of intestinal ischemia
  • Severe renal impairment (eGFR<
    15 mL/min/1.73 m2) or end-stage renal disease
  • Moderate and severe hepatic impairment (Child-Pugh B or C)
  • History of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions
  • Hypersensitivity to ZELNORM
Indication

ZELNORMTM (tegaserod) is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).

Warnings and Precautions

Cardiovascular Ischemic Events, Including Major Adverse Cardiovascular Events (MACE): Stroke, MI, and cardiovascular death have been reported in adults taking ZELNORM who had an increased risk of developing an adverse cardiovascular event based on their medical history.

Female patients less than 65 years of age should be assessed for a history of cardiovascular disease and cardiovascular risk factors prior to treatment with ZELNORM.

Discontinue ZELNORM in patients who experience an MI, stroke, TIA, or angina. Evaluate the risks and benefits of continued use of ZELNORM in patients who develop evidence of cardiovascular ischemic heart disease (e.g., coronary artery disease) or experience changes in health status that could increase cardiovascular risk during treatment with ZELNORM.

Ischemic Colitis: Ischemic colitis and other forms of intestinal ischemia have been reported postmarketing in patients receiving ZELNORM. Discontinue ZELNORM in patients who develop symptoms of ischemic colitis, such as rectal bleeding, bloody diarrhea, or new or worsening abdominal pain.

Volume Depletion Associated with Diarrhea: In postmarketing experience, serious consequences of diarrhea including hypovolemia, hypotension, and syncope have been reported in patients treated with ZELNORM. Avoid use of ZELNORM in patients who are currently experiencing or frequently experience diarrhea. Instruct patients to discontinue ZELNORM and contact their healthcare provider if severe diarrhea, hypotension, or syncope occur.

Suicidal Ideation and Behavior: Monitor all ZELNORM-treated patients for clinical worsening of depression and emergence of suicidal thoughts and behaviors, especially during the initial few months of treatment. Counsel family members and caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Instruct patients to immediately discontinue ZELNORM and contact their healthcare provider if their depression is persistently worse or they are experiencing emergent suicidal thoughts or behaviors.

Common Adverse Reactions (incidence >2% and greater than placebo)

The most common adverse reactions in 3 placebo-controlled trials of ZELNORM in female IBS-C patients less than 65 years of age: headache (14% vs 10% placebo), abdominal pain (11% vs 10%), nausea (8% vs 7%), diarrhea (8% vs 3%), flatulence (6% vs 5%), dyspepsia (4% vs 3%), and dizziness (4% vs 3%).

Use in Specific Populations

Pregnancy: Safety and effectiveness not established

Lactation: Breastfeeding not recommended

Pediatric use: Safety and effectiveness not established

Geriatric use: Not indicated for patients 65 years of age and older

Severe renal conditions: Contraindicated

Moderate to severe hepatic conditions: Contraindicated

Please click here for full Prescribing Information.

This site is intended for U.S. Healthcare Professionals only. Distributed by: Alfasigma USA, Inc. Covington, LA 70433 © 2019 Alfasigma USA, Inc. ZELNORM is a trademark of Alfasigma USA, Inc. All rights reserved. 07/2019 ZEL19-009

You are about to go to another site.

Do you want to leave this site?

X

Please verify that you are a U.S. Healthcare Professional

This information is intended for U.S. Healthcare Professionals

X